Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lederlin

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2007
Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2P Morel, P Gaulard, C Gisselbrecht, et al.
Haematologica|May 9, 2000
Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'AdulteR O Casasnovas, C Haioun, C Dumontet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2000
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte studyC Haioun, E Lepage, C Gisselbrecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997
Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 yearsY Bastion, J Y Blay, M Divine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'AdulteC Haioun, E Lepage, C Gisselbrecht, et al.
Leukemia|January 17, 2003
Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patientsF Maloisel, L Benboubker, M Gardembas, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Tumor necrosis factor alpha release is a major biological event associated with rituximab treatmentJ Bienvenu, R Chvetzoff, G Salles, et al.
Blood|January 3, 2001
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluationP Colombat, G Salles, N Brousse, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2007
Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2P Morel, P Gaulard, C Gisselbrecht, et al.
Haematologica|May 9, 2000
Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'AdulteR O Casasnovas, C Haioun, C Dumontet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2000
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte studyC Haioun, E Lepage, C Gisselbrecht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997
Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 yearsY Bastion, J Y Blay, M Divine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'AdulteC Haioun, E Lepage, C Gisselbrecht, et al.
Leukemia|January 17, 2003
Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patientsF Maloisel, L Benboubker, M Gardembas, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Tumor necrosis factor alpha release is a major biological event associated with rituximab treatmentJ Bienvenu, R Chvetzoff, G Salles, et al.
Blood|January 3, 2001
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluationP Colombat, G Salles, N Brousse, et al.
Pageof 8